Management of Incidental Pancreatic Cysts: A White Paper of the ACR Incidental Findings Committee

Alec J. Megibow, MD, MPH, Mark E. Baker, MD, Desiree E. Morgan, MD, Ihab R. Kamel, MD, PhD, Dushyant V. Sahani, MD, Elliot Newman, MD, William R. Brugge, MD, Lincoln L. Berland, MD, Pari V. Pandharipande, MD, MPH

Abstract

The ACR Incidental Findings Committee (IFC) presents recommendations for managing pancreatic cysts that are incidentally detected on CT or MRI. These recommendations represent an update from the pancreatic component of the JACR 2010 white paper on managing incidental findings in the adrenal glands, kidneys, liver, and pancreas. The Pancreas Subcommittee—which included abdominal radiologists, a gastroenterologist, and a pancreatic surgeon—developed this algorithm. The recommendations draw from published evidence and expert opinion, and were finalized by informal iterative consensus. Algorithm branches successively categorize pancreatic cysts based on patient characteristics and imaging features. They terminate with an ascertainment of benignity and/or indolence (sufficient to discontinue follow-up), or a management recommendation. The algorithm addresses most, but not all, pathologies and clinical scenarios. Our goal is to improve quality of care by providing guidance on how to manage incidentally detected pancreatic cysts.

Key Words: Pancreas, cyst, intraductal papillary mucinous neoplasm (IPMN), incidental finding

OVERVIEW OF THE ACR INCIDENTAL FINDINGS PROJECT

The core objectives of the Incidental Findings Project are to (1) develop consensus on patient characteristics and imaging features that are required to characterize an incidental finding; (2) provide guidance to manage such findings in ways that balance the risks and benefits to patients; (3) recommend reporting terms that reflect the level of confidence regarding a finding; and (4) focus future research by proposing a generalizable management framework across practice settings. The Incidental Findings Committee (IFC) generated its first white paper in 2010, addressing four algorithms for managing incidental pancreatic, adrenal, kidney, and liver findings [1].

THE CONSENSUS PROCESS: THE Pancreatic CYST ALGORITHM

The current paper represents the first revision of the IFC’s recommendations regarding incidental pancreatic cysts. The process of developing this algorithm included naming
a Subcommittee Chair, who appointed four additional abdominal radiologists, a gastroenterologist, and a pancreatic surgeon. The Subcommittee then developed and gained consensus on a preliminary version of the algorithm. The Subcommittee used published evidence as their primary source. Where evidence was not available, they invoked the collective expertise of their team. The preliminary algorithm underwent review by additional members within the IFC, including the Body Commission Chair, the IFC Chair, and additional IFC Subcommittee Chairs. The revised algorithm and corresponding white paper draft were submitted to additional ACR stakeholders to gain input and feedback. Consensus was obtained iteratively after successive reviews and revisions. After completion of this process, the algorithm and white paper were finalized. The IFC’s consensus processes meet policy standards of the ACR. However, they do not meet any specific, formal national standards. This algorithm and set of recommendations does not represent policy of the ACR Practice Guidelines or the ACR Appropriateness Criteria. Our consensus may be termed “guidance” and “recommendations” rather than “guidelines,” which has a more formal definition.

ELEMENTS OF THE FLOWCHARTS: COLOR CODING

The algorithm consists of multiple flowcharts (Figs. 1-4). Within each flowchart, yellow boxes indicate using or acquiring clinical data (eg, lesion size, interval stability), green boxes describe recommendations for action (eg, follow-up imaging or biopsy), and red boxes indicate that work-up or follow-up may be terminated (eg, if the finding is benign or indolent). To minimize complexity, each algorithm addresses most—but not all—imaging appearances and clinical scenarios. Radiologists should feel comfortable deviating from the algorithm in circumstances that are not represented in the algorithm, based on the specific imaging appearance of the finding.

**Fig 1.** Flowchart (Chart 1) specifying the management of incidental pancreatic cysts <1.5 cm. EUS = endoscopic ultrasound; FNA = fine needle aspiration; MPD = main pancreatic duct.
NATURE AND SCOPE OF THE PROBLEM

Prevalence of Pancreatic Cysts

In a 2013 study of the National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) registry, the estimated number of pancreatic cysts in the U.S. population between 40 and 84 years old was 3,428,874, with an overall cyst prevalence of 2.5% [2]. Increased use of cross-sectional imaging has led to increased detection of such cysts in recent years; 2.2% of upper abdominal CT examinations and 19.6% of MRI examinations report a pancreatic cyst [3-5]. Although commonly used management guidelines assume knowledge of a specific pancreatic cyst type [6-8], many cysts detected at imaging are indeterminate. Therefore, radiologists cannot reliably predict an indolent versus aggressive course at the time of detection.

In patients with a family history or genetic predisposition to pancreatic ductal adenocarcinoma (PDAC), there is an increased prevalence of pancreatic cystic neoplasms [9]. However, increased risk of malignant transformation of a given cyst in such populations is questionable. In a study of 300 patients with intraductal papillary mucinous neoplasm (IPMN) and a first-degree relative with PDAC, progression to pancreatic cancer was the same as the controls, suggesting that
follow-up strategies need not be altered for patients with cysts <3 cm [10]. Patients with specific hereditary syndromes (eg, Peutz-Jehgers and familial atypical multiple mole melanoma syndromes) are at higher risk of PDAC, but it is unknown if the presence of a pancreatic cyst increases the risk in these patients.

**Clinical Importance**

The most frequently encountered pancreatic cysts include IPMN, serous cystadenoma (SCA), mucinous cystic neoplasm with ovarian stroma (MCN), solid pseudopapillary epithelial neoplasm, cystic pancreatic neuroendocrine tumor (cPNET), and pseudocyst [3]. Rare cysts include true epithelial cyst, lymphoepithelial cyst, and mucinous non-neoplastic cyst. IPMN is further subdivided into branch duct (BD), main duct, and combined forms.

Among these, four have no malignant potential: pseudocyst, true epithelial cyst, lymphoepithelial cyst, and mucinous non-neoplastic cyst. Malignancy occurs virtually only in mucinous cysts. SCA is considered a nonmalignant lesion, although exceedingly rare malignant serous tumors have been reported. IPMN can progress from lower to higher grades of dysplasia and, ultimately, PDAC [11]. Malignancy rates in IPMN are reported as 12%-47% for BD-IPMN, whereas combined form and main duct forms have essentially identical malignancy rates of 38%-65% and 38%-68%, respectively [3]. The mucinous cystic tumor with ovarian stroma has a malignancy rate between 10% and 17% [12,13]. Other rarer cystic lesions, such as solid pseudopapillary epithelial neoplasm and cPNET, tend to harbor features that suggest a specific diagnosis, usually leading to surgical removal.
In a classic paper, small (<4 mm) pancreatic cysts were found in 24.3% of 300 consecutive all-cause autopsies [14]. Coupled with the now-accepted concept of an adenoma-carcinoma sequence [15], an incidentally detected cyst may be a precursor to PDAC. However, observational data on BD-IPMN suggest that lesions ≤2 cm are indolent with only a small fraction progressing to malignancy [16-20] even when mural nodules are present [21]. Accurate rates of transition to malignancy for small, incidental pancreatic cysts remain unknown.

Pancreatic cysts may reflect an elevated whole-gland risk for developing PDAC at a location within the pancreas other than within the cyst; multiple authors have observed PDAC separate from a cyst [22-25]. In a large Veterans Affairs study, the incidence of pancreatic cancer in patients with previously diagnosed cysts was 5.08 per 1,000 patient-years compared with 0.32 in patients without cysts; however, the location of such cancers relative to cysts was not reported [26]. Patients with cysts who are less than 65 years old also have been reported to have increased all-cause mortality relative to those without cysts; the same is not true for patients who are aged ≥65 years [24].

**Significance of Small Pancreatic Cysts**

Most diagnostic uncertainty is centered on pancreatic cysts <2.5 cm. Helpful queries include the following: (1) Is the cyst mucinous? (2) If mucinous, what is its relation to the main pancreatic duct (MPD)? and (3) If mucinous, are mural nodules present? Several studies suggest that referring physicians are comfortable with imaging surveillance for small BD-IPMN without mural nodules [16,17,21,27], which is supported by pathology studies confirming a low rate of malignant transformation [28]. However, even small so-called “Sendai-negative” cysts may have microscopic invasion into the adjacent MPD, underscoring the limitations of imaging for identifying aggressive lesions [29,30]. Presence or development of a
mural nodule is a suspicious finding even in cysts that do not grow [31].

**Role of Endoscopic Ultrasound–Guided Fine Needle Aspiration**

Endoscopic ultrasound (EUS) coupled with pancreatic cyst fine needle aspiration (FNA) has been performed with increasing frequency in the past 5 years to (1) characterize a cyst as mucinous or likely mucinous; (2) determine if the cyst connects to the main duct; or (3) detect mutations in the cyst fluid that might predict future behavior. Cyst aspiration can help identify a mucinous cyst based on the presence of non-gut mucin (Alcian blue stain positive) and carcinoembyonic antigen (CEA) in concentrations of ≥192 ng/mL [32]; CEA levels <5 ng/mL suggest pseudocyst or SCA. Amylase levels of >250 IU/L suggest pseudocyst [33]; levels >18,000 IU/L establish this diagnosis. Two milliliters of fluid, corresponding to a cyst diameter of 1.7 cm, is sufficient to perform cytology and obtain CEA and amylase levels in experienced hands [34]. Assays for molecular markers of mutations such as K-ras, GNAS, mRNA 21, and glucose to differentiate mucinous from nonmucinous cysts have been advocated [35]. Cytology from the cyst may reveal dysplastic cells. Aspiration may improve discrimination of benign from malignant cysts [36,37], especially when combined with information from imaging, cytology, and molecular markers [38]. A recent retrospective multi-institutional review suggests that a large panel of markers, when combined with imaging and clinical data, can classify cysts with 90%-100% sensitivity and 92%-98% specificity, thereby reducing unnecessary operations by 91% [39]. Although commercial laboratories analyze cyst fluid and generate a report of the relative risk of an individual cyst [40], the incremental benefit beyond imaging and cytology has been called into question in several peer-reviewed publications [41,42].

---

**Fig 4.** Flowchart (Chart 4) specifying the management of incidental pancreatic cysts in patients ≥80 years old at presentation. EUS = endoscopic ultrasound; FNA = fine needle aspiration; MPD = main pancreatic duct; SCA = serous cystadenoma.
Length of Follow-up

We previously recommended 2-year follow-up to establish cyst stability, concluding that stable cysts were benign or indolent [1]. Although this approach remains valid for most cysts [43], authors have documented delayed growth in cysts that were unchanged for several years [44,45]. We considered this observation, as well as new knowledge concerning age-related outcomes [24] and cysts as a marker for elevated whole-gland PDAC risk [24,25], when updating our recommendations.

For most patients, we advocate 9- to 10-year follow-up, terminating at the age of 80 years (Figs. 1-3). For patients who are <65 years old at the time of initial cyst detection, a follow-up terminating at age 80 will exceed the 9- to 10-year length, but may be prudent [24]; such decisions regarding additional follow-up should be determined at the individual patient level. For patients ≥80 years old at the time of initial cyst detection, a separate follow-up schedule is provided (Fig. 4). With our approach, many older patients will not undergo surveillance for the full follow-up period, whereas younger patients may be subject to lengthier monitoring in comparison. The follow-up intervals are based on experiential observations, and are not from randomized controlled studies.

Follow-up beyond 80 years of age, for a cyst that was first identified at <80 years, is generally not advised, as indicated above. The exception is when a cyst is discovered in a patient who is close to—but not yet—80 years of age. When this occurs, case-by-case decisions for ongoing surveillance should be based on individual patient characteristics (ie, overall patient health, willingness to undergo treatment if needed) and the accumulated knowledge about the cyst. In such circumstances, management can shift to the same flowchart that addresses cysts initially detected at ≥80 years of age (Fig. 4).

Challenges to a Perfect Algorithm

The natural history of incidental pancreatic cysts remains uncertain, and our recommendations cannot be simple or entirely definitive. Since 2010, several multi-institutional and specialty society consensus papers, meta-analyses, and large-scale observational studies have appeared [1,21,34,46-50], but the quality of evidence has been characterized as poor or inconclusive, and conclusions remain controversial [34]. Physicians must discuss such uncertainty with their patients, integrating patients’ risk tolerance, physicians’ clinical judgment, and local expertise into management decisions. When local expertise is limited, referrals to sites of clinical excellence are strongly encouraged.

REPORTING CONSIDERATIONS

The following six elements must be reported when an incidental pancreatic cyst is detected on a CT or MRI study:

1. Cyst morphology, location
2. Cyst size
3. Possible communication with MPD
4. Presence of “worrisome features” and/or “high-risk stigmata”
5. Growth on follow-up examination
6. Multiplicity

1. Cyst Morphology, Location

As mentioned, the most frequently encountered pancreatic cysts include IPMN, SCA, MCN, solid pseudopapillary epithelial neoplasm, cPNET, and pseudocyst. Rare cysts include simple epithelial cyst, lymphoepithelial cyst, and mucinous non-neoplastic cyst. IPMN is further subdivided into BD, main duct, and combined forms. Cysts that are less than 10 mm are difficult or impossible to specifically characterize. Cysts measuring 1-3 cm are often “indeterminate” unless communication with the MPD can be established. If duct communication is established, the cyst is classified as either BD or combined-type IPMN. Cysts ≥3 cm can be classified as oligocystic, microcystic, macrocystic, unilocular, or multilocular [51]. If calcification is present within a cyst, its location should be reported. A cystic lesion with central calcification is most likely an SCA, whereas a cyst with peripheral calcification is likely an MCN. Peripheral calcification in MCNs is more strongly associated with frank malignancy [52].

Every attempt should be made to establish the diagnosis of SCA or pseudocyst. SCA displays characteristic features in >60% of cases [53], although “atypical” morphology can also be seen in a large proportion of cases [6,54]. Clinical history and amylase levels in the cyst fluid of about 18,000 IU/L may help diagnose a pseudocyst; however, elevated amylase is common in mucinous cysts [55]. We assume that incidental cysts that cannot be characterized when detected are likely to be mucinous (eg, IPMN). Follow-up imaging and/or EUS with FNA is typically needed.

Knowledge of a cyst’s location (uncinate process, head, neck, body, or tail) is important when evaluating comparison studies and can also aid in differential diagnosis. For example, MCNs are common in the pancreatic
tail, whereas BD-IPMNs are most frequent in the pancreatic head/uncinate.

### 2. Cyst Size

Despite the importance of a cyst’s size for management decisions, there are no uniformly accepted measurement methods, even in widely utilized consensus guidelines [7,48]. We recommend recording a single measurement of the greatest length of the cyst in the long axis on either the axial or coronal image, and also reporting the corresponding image and series numbers. The image containing the measurement cursor must be archived with the clinical dataset. Although more precise measurements could be gleaned from three-dimensional (3D) images, this simpler approach is more reproducible.

### 3. Relation to Main Pancreatic Duct

Radiologists should report whether there is communication between the cyst and the MPD, because this is necessary for the cyst to be a BD-IPMN. CT with 3D reconstructions or MRI with MRCP (Magnetic Resonance Cholangiopancreatography) are excellent and equivalent to EUS to establish duct communication [56,57]. However, it may not always be possible to ascertain the presence of duct communication. Our algorithm accounts for such instances (Fig. 2B). The importance of reporting cyst communication to the main duct is that for some small BD-IPMNs (Fig. 2A), slightly less aggressive management can be pursued compared with a circumstance in which this diagnosis is less certain.

BD-IPMN should be further separated into pure versus combined forms. In the pure form, the lesion is connected to the MPD by a thin neck. In the combined form, in which the MPD is also involved, the MPD diameter is variable. For all BD-IPMN, the widest diameter of the MPD should be recorded, even if away from the cyst. A dilated MPD is a suspicious feature with BD-IPMN, and should be immediately investigated by EUS and FNA to determine further management [58,59].

Table 1. Worrisome features and high-risk stigmata

<table>
<thead>
<tr>
<th>Worrisome Features</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cyst ≥3 cm</td>
</tr>
<tr>
<td>Thickened/enhancing cyst wall</td>
</tr>
<tr>
<td>Nonenhancing mural nodule</td>
</tr>
<tr>
<td>Main pancreatic duct caliber ≥7 mm*</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>High-Risk Stigmata</th>
</tr>
</thead>
<tbody>
<tr>
<td>Obstructive jaundice with cyst in head of pancreas</td>
</tr>
<tr>
<td>Enhancing solid component within cyst</td>
</tr>
<tr>
<td>Main pancreatic duct caliber ≥10 mm in absence of obstruction</td>
</tr>
</tbody>
</table>

*From Tanaka et al [48].
†Based on Kang et al [59].

5. Growth on Follow-up Examination

Although an accepted definition of significant “growth” is not established in the literature, we recommend that radiologists report whether growth has occurred on follow-up examinations according to the following criteria: for cysts <0.5 cm, growth is represented by a 100% increase in long-axis diameter; for cysts ≥0.5 cm and <1.5 cm, a 50% increase in long-axis diameter; and for cysts ≥1.5 cm, a 20% increase in long-axis diameter.

Though most clinicians, surgeons, and radiologists believe that growth indicates possible progression toward high-grade dysplasia or malignancy, this assumption has been questioned [34]. Even so, growth remains the most widely utilized parameter for long-term surveillance.

When possible, radiologists should also report a cyst’s growth rate. Several authors have shown that a more rapid growth rate (>2 mm/year) can help separate aggressive from indolent cysts [60,61].

6. Multiplicity

Radiologists should report the presence of multiple cysts. The cyst with the longest dimension should be used as
the index lesion. However, each cyst must be assessed for growth and for worrisome features and high-risk stigmata on initial and follow-up examinations, because these features may be present in any of the cysts. Our algorithm applies to patients with single or multiple incidental pancreatic cysts because the literature is not clear about different outcomes for multiple cysts [62,63]. The importance of multifocal IPMN has been studied by several groups in patients with >2 cysts [8,62-64]. Two groups found an increased risk of high-grade dysplasia or malignancy when compared to a solitary IPMN cohort [62,64], whereas two groups did not [8,63].

INCLUSION/EXCLUSION CRITERIA FOR USE OF THE ALGORITHM

Our algorithm consists of five separate flowcharts (Figs. 1, 2A, 2B, 3, 4). These should be applied to incidentally detected pancreatic cysts only if the patient is both an adult (≥18 years of age) and asymptomatic. The algorithm should not be used whenever there is a potentially related sign or symptom (eg, jaundice, anorexia, weight loss, palpable mass, or steatorrhea) or a relevant abnormal laboratory value (eg, elevated amylase). For patients with abdominal pain, to determine if the algorithm should be used, the radiologist should assess whether the pain may be attributable to the cyst and should consider direct consultation with the patient and/or referring physician. If the patient becomes symptomatic while under surveillance, use of the algorithm should be terminated and the patient should be referred for surgical consultation, depending on other clinical factors.

IMPLICATIONS OF IMAGING AND CLINICAL FEATURES

Five Common Principles of our Algorithm

(1) All incidental cysts should be presumed mucinous, unless the cyst has definitive features of an alternative histology (eg, SCA) or has been proven by aspiration not to be mucinous. Such presumed mucinous cysts should be followed or considered for surgery [16,19,46]. We generally recommend 9- to 10-year follow-up with varying schedules, based on initial size. If a cyst grows, the frequency of follow-up should increase and/or EUS with FNA should be considered.

(2) Cyst size directs follow-up or intervention. Although our cyst size thresholds (ie, <1.5 cm, 1.5-2.5 cm, >2.5 cm) differ from the commonly used 3 cm threshold [48], our choices are sensitive to studies of surgically resected “Sendai-negative” cysts <3 cm, which have shown that high-grade dysplasia or frank malignancy may occur in cysts of this size [30,65-67].

(3) Because the flowcharts apply to a range of cyst sizes, growth may require shifting from one flowchart to another, most commonly when a cyst grows from <1.5 to ≥1.5 cm. Such shifts may also be appropriate when a cyst is first discovered in patients who are close to 80 years of age, as described above (“Nature and Scope of the Problem” section). In general, a new 9- to 10-year follow-up period is not recommended when such a shift occurs; rather, decisions concerning total follow-up length should be tailored to the patient’s circumstance. Alternatively, it is appropriate to consider direct sampling of a growing cyst (ie, EUS and FNA).

(4) Development of “worrisome features” or “high-risk stigmata,” as described above (“Reporting Considerations” section), should prompt EUS/FNA and surgical consultation. The exception is that cysts ≥3 cm without any additional “worrisome features” or “high-risk stigmata” can alternatively be followed.

(5) Comparison with prior imaging studies is crucial, including those where the pancreas is frequently visualized, such as chest CT, spine CT or MRI, PET/CT, and abdominal ultrasound. Prior studies should be reviewed for stability and features. The date of a prior study can be used as a baseline to establish a follow-up schedule.

Overview of the Algorithm

Chart 1 (Fig. 1) addresses patients with cysts <1.5 cm. Patients are divided into two groups (<65 years and 65-79 years). Cysts are rarer in younger patients [2] but are associated with higher all-cause mortality [24]. Follow-up is therefore less frequent for patients ≥65 years (initial follow-up is every 2 years versus yearly) [43]. We do not formally recommend that each of these cysts be specifically characterized at the time of detection. Rather, we advise the default assumption that all are mucinous (eg, small IPMN) and require observation [68], knowing that the majority will be indolent [16,27,69].

One exception is the so-called “white dot” (<5 mm) lesions seen on T2-weighted MRI. Based on limited
EUS with FNA. The latter approach can establish if the cyst is mucinous (Fig. 2B). The flowchart depicts two pathways: close imaging follow-up versus direct EUS and FNA at the time of detection. Following this pathway assumes that data obtained from aspirated fluid and serum will further risk-stratify the cyst; however, unless state-of-the-art biomarker and genetic analysis is possible, little yield over imaging is expected [39,70].

Charts 2A and B (Fig. 2) separate 1.5- to 2.5-cm cysts by whether they can be definitively characterized as BD-IPMN or are indeterminate, based on communication with the MPD. If duct communication is present (Fig. 2A), the follow-up schedule is based on initial cyst size, where cysts from 1.5 to 1.9 cm at presentation are followed at yearly intervals for 5 years, then every 2 years for 4 years. Cysts between 2.0 and 2.5 cm at presentation are followed at 6-month intervals for 2 years, then yearly for 2 years, and then every 2 years for 6 years. An alternative to the suggested follow-up schedule is for direct EUS and FNA at the time of detection. Following this pathway assumes that data obtained from aspirated fluid and serum will further risk-stratify the cyst; however, unless state-of-the-art biomarker and genetic analysis is possible, little yield over imaging is expected [39,70].

Chart 2B provides guidance for 1.5- to 2.5-cm cysts that are not clearly mucinous (Fig. 2B). The flowchart depicts two pathways: close imaging follow-up versus EUS with FNA. The latter approach can establish if the cyst is mucinous and guide related decision making [71].

Chart 3 (Fig. 3) addresses cysts that are >2.5 cm at initial detection. If a “benign” histology such as SCA can be diagnosed by imaging or aspiration, follow-up will depend on symptoms, although a symptomatic SCA or one >4 cm may require surgical removal because of size and/or expected growth [72]. Pseudocysts are excluded because most patients will be (or will have recently been) asymptomatic. Other cysts >2.5 cm should be evaluated for the presence (high-risk) or absence (low-risk) of previously defined worrisome features and/or high-risk stigmata. Low-risk cysts can be carefully followed (even if ≥3 cm), but high-risk cysts should be sent immediately for EUS, FNA, and surgical evaluation. Many centers aspirate all cysts ≥3 cm and recommend resection if mucinous [73]. We recommend that any cyst undergo EUS and FNA before resection, to minimize unnecessary surgery.

Chart 4 (Fig. 4) primarily addresses patients ≥80 years of age with initial detection of an incidental pancreatic cyst. Recommendations are based on a cyst size threshold of 2.5 cm, overall health, and patient preferences. We do not advise following cysts in patients who are not surgical candidates. As described above (“Nature and Scope of the Problem” section), if a cyst is incidentally discovered when a patient is close to—but not yet—80 years of age, Figure 4 may be used to guide further management when the patient reaches 80 years of age.

IMAGING PROTOCOL OPTIMIZATION

Follow-up imaging may be performed with either MRI with contrast-enhanced sequences or “pancreas-protocol” multiple detector CT. MRI avoids the cumulative radiation exposure of multiple follow-up CT examinations, but MRI has not been shown to be superior to pancreas-protocol CT scanning for detecting worrisome features or PDAC [20,74-76].

Regardless of the modality, intravenous contrast, multiphase acquisitions, and thin sections for 3D visualization are generally needed. Sixteen-slice or greater multiple detector CT scanners acquire submillimeter slices with isotropic voxels and allow reformatted thicker slices (3-5 mm). Pancreatic-phase images should begin about 50 seconds after initiating the intravenous contrast injection. Injection rates of 4-5 mL/s may optimally display peripancreatic vasculature and maximize pancreatic enhancement. A second phase is recommended at approximately 80 seconds to evaluate the liver [77,78].

MRI studies can be performed at 1.5 or 3T. Fat-suppressed T2-weighted images (single shot or breath hold) and gadolinium-enhanced T1-weighted gradient-recalled echo sequences in arterial, early portal, and late portal phases are suggested [79]. MRCP can help to establish if the cyst communicates with the MPD, assisted by 3D analysis of source data (thin slices). Routinely using contrast material for MRI follow-up is controversial. Noncontrast MRI has shorter scan times and lower cost, with little difference in detecting evolving dysplastic changes [80,81]. However, contrast-enhanced sequences may help detect enhancement within mural nodules (high-risk stigma), and the pancreatic phase improves the ability to detect metachronous PDAC elsewhere. An abbreviated MRI examination combining T2-weighted and gadolinium-enhanced acquisitions has been shown to be equivalent to standard MRI for the purposes of follow-up [81].

Specifics of pancreatic protocols for CT and MRI are summarized in a joint statement from the American Pancreatic Association and the Society of Abdominal Radiology [82]. These protocols have also been adopted into National Comprehensive Cancer Network (NCCN) guidelines for pancreatic imaging (version 1.2016).
CONCLUSION
This updated algorithm addresses the most current information concerning the prolonged time frame for pancreatic cyst growth and limited ability to assess the malignancy risk of a given cyst. Specific criteria for how to measure the cyst, a definition of growth, and varying surveillance strategies based on patient characteristics and initial cyst size are proposed.

TAKE-HOME POINTS
- We propose an updated algorithm for reporting incidental pancreatic cysts, stratified by patient and imaging features.
- Five properties that define our new algorithm include the following: (1) cysts should be managed as mucinous unless proven otherwise, (2) broad use of EUS with FNA for more refined cyst characterization, (3) more specific definition of cyst measurement and growth criteria, (4) follow-up periods of 9-10 years in most patients, and (5) modified management for patients ≥80 years of age.
- Throughout, we emphasize the importance of shared decision making between patients and physicians for successfully managing incidental pancreatic cysts.

ACKNOWLEDGMENTS
The ACR thanks the Society of Abdominal Radiology (SAR) and the Society of Computed Body Tomography and Magnetic Resonance (SCBT-MR) for their contributions to and endorsement of the recommendations in this white paper. In addition, the authors thank Dr William Mayo-Smith (IFC Adrenal Subcommittee Chair), Dr Brian Herts (IFC Renal Subcommittee Chair), and Dr Richard Gore (IFC Liver Subcommittee Chair), who provided substantial input and feedback for this white paper as members of the ACR IFC’s Executive Committee.

REFERENCES


